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Abstract
Role of GLP-1 and GIP in beta cell compensatory responses to beta cell attack and insulin resistance were examined in
C57BL/6 mice lacking functional receptors for GLP-1 and GIP. Mice were treated with multiple low dose streptozotocin or
hydrocortisone. Islet parameters were assessed by immunohistochemistry and hormone measurements were determined
by specific enzyme linked immunoassays. Wild-type streptozotocin controls exhibited severe diabetes, irregularly shaped
islets with lymphocytic infiltration, decreased Ki67/TUNEL ratio with decreased beta cell and increased alpha cell areas. GLP-
1 and GIP were co-expressed with glucagon and numbers of alpha cells mainly expressing GLP-1 were increased. In contrast,
hydrocortisone treatment and induction of insulin resistance increased islet numbers and area, with enhanced beta cell
replication, elevated mass of beta and alpha cells, together with co-expression of GLP-1 and GIP with glucagon in islets. The
metabolic responses to streptozotocin in GLP-1RKO and GIPRKO mice were broadly similar to C57BL/6 controls, although
decreases in islet numbers and size were more severe. In contrast, both groups of mice lacking functional incretin receptors
displayed substantially impaired islet adaptations to insulin resistance induced by hydrocortisone, including marked
curtailment of expansion of islet area, beta cell mass and islet number. Our observations cannot be explained by simple
changes in circulating incretin concentrations, suggesting that intra-islet GLP-1 and GIP make a significant contribution to
islet adaptation, particularly expansion of beta cell mass and compensatory islet compensation to hydrocortisone and
insulin resistance.
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Introduction
Glucagon-like peptide-1 (GLP-1) together with the sister
incretin hormone gastric inhibitory polypeptide (GIP) are secreted
from intestinal L-cell and K-cells in response to feeding and exert
pleiotropic metabolic effects [1–5]. Notably GLP-1 and GIP exert
key actions on islets, including stimulation of insulin release,
augmentation of glucose sensitivity, promotion of beta cell
replication and protection from both beta-cell apoptosis and
cytotoxic attack. Important and emerging actions are also evident
at extrapancreatic sites [1,5]. Apart from positive actions on
cognition via effects at the hippocampus, the effects of the two
peptides differ, with GIP inhibiting gastric acid secretion and
exerting anabolic effects on both adipose tissue and bone whereas
GLP-1 inhibits gastric emptying and satiety, while affording
cardioprotection [5–8]. The antidiabetic effects of GLP-1 receptor
activation have been harnessed for type 2 diabetes with the
development of stable GLP-1 mimetics as a new class of
therapeutic drugs [9,10]. DPPIV inhibitors which normally block
the rapid enzymatic breakdown of both incretin hormones and
additionally augment the actions of GIP have also been introduced
[11].
Intestinal L-cells and pancreatic islet alpha cells both express the
proglucagon gene which is differentially processed in a tissue
specific manner, yielding GLP-1 in the gut and glucagon in the
islets. The classical view is that in islet alpha cells, proglucagon is
processed primarily by PC2 to generate the 29 amino acid
sequence of glucagon plus glicentin-related pancreatic polypeptide
(GRPP) and major proglucagon fragment, whereas the progluca-
gon precursor is processed by PC1/3 in intestinal L-cells to
generate GLP-1 together with GLP-2, glicentin, oxyntomodulin
and GRPP [3]. However, recent observations challenge this view,
showing that islet alpha cells express PC1/3 and produce
significant amounts of GLP-1 [12–15] which has been confirmed
in human islets using MALDI-TOF mass spectrometry as GLP-
1(7–36) and GLP-1(7–37) [16]. Further, alpha cell expression of
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GLP-1 is enhanced under situations of increased insulin demand
and beta cell stress such as glucose toxicity, chemical insult and
partial pancreatectomy [14,15,17–19]. Consistent with this view,
in vitro studies indicate that isolated islets secrete GLP-1 upon
alpha cell stimulation with arginine and that chemical blockade of
GLP-1 action suppresses concomitant insulin release [20].
Although less well studied, bioactive GIP is also synthesized and
released by islet alpha-cells [21]. Co-localisation of GIP and
glucagon has been demonstrated using highly specific antibodies in
alpha cells of many species, including Burmese phython, rat and
human [21]. Studies by the Vancouver group have also
demonstrated GIP messenger RNA in islets and confirmed that
bioactive GIP is secreted by islets in response to arginine
stimulation [21]. It appears that both GIP (1–42) and GIP (1–
30) are expressed due to processing of proGIP by PC1/3 and PC2.
Indeed, the major peptide form in alpha-cells might be GIP (1–30)
due to the relative abundance of PC2 under normal circumstances
and its ability to mediate a second C-terminal cleavage of GIP (1–
42) liberating the truncated peptide [22]. These two forms have
identical biological effects at the GIP receptor, including
promotion of insulin secretion and lowering of blood glucose [23].
Although significant evidence for islet alpha cell production of
GLP-1 and GIP has been gathered which suggests a biological role
[14,15,16,18,21,24–28], there is no real evidence that this plays
any part in the regulation of islet function. It is unlikely that islet-
derived GLP-1 and GIP contribute significantly to circulating
incretin concentrations or the extra-pancreatic actions of the
peptides, but locally released GLP-1 and GIP might exert
important effects on neighboring islet cells. Thus, on the basis of
known actions of the incretins [9,5,29], it can be hypothesized that
local islet production of incretin peptides is likely to enhance beta-
cell function and survival in response to cytotoxic attack and
increased demand imposed by insulin resistance.
In this paper, we have used incretin receptor knock-out mice
and wild-type controls to evaluate the role of islet and intestinal L-
and K-cell derived GLP-1 and GIP in relation to alterations in
number, morphology and function of the islets and beta-cells in
animal models of beta cell insult and insulin resistance, induced by
multiple low dose streptozotocin or hydrocortisone treatment. The
results provide novel information on the regulation of beta cell
mass, functional consequences of intra-islet expression of incretin
hormones and add weight to the debate concerning strategies for




Adult 12 week old male wild-type C57BL/6 mice and both
GLP-1RKO and GIPRKO mice on the same C57BL/6 genetic
background were bred in house at the Biomedical and Behavioural
Research Unit (BBRU) at University of Ulster, Coleraine. The
original background of these incretin receptor knockout mice are
described elsewhere [31,32]. Mice were housed individually in an
air-conditioned room at 2262uC with 12 h light and 12 h dark
cycle. Standard rodent maintained pellet diet (Trouw Nutrition,
Northwich, UK) and drinking water were available ad libitum. All
animal experiments were carried out in accordance with the UK
Animals (Scientific Procedures) Act 1986 and approved by the
University of Ulster Animal Ethics Review Committee. All
necessary steps were taken to ameliorate any potential animal
suffering and animals were sacrificed by lethal inhalation of CO2
followed by cervical dislocation.
In vivo studies
Over a 5-day period, incretin receptor knockout mice and age-
matched controls (n = 6 in each group, fasted for 4 h) received
once daily i.p. injections (13:00 h) of saline vehicle (0.9% (w/v),
NaCl) or streptozotocin (50 mg/kg body wt; made freshly in 0.1 M
sodium citrate buffer, pH 4.5). Food intake, body weight and
blood glucose were monitored daily. Mice were culled at 5 days
post treatment to procure pancreata and terminal blood. In a
second series of experiments, incretin receptor knockout mice and
controls (n = 6) received once daily i.p. injections (09:00 h) of saline
vehicle (0.9% (w/v), NaCl) or hydrocortisone (70 mg/kg body wt;
made freshly in saline) for 10 days. Food intake, body weight and
blood glucose were monitored daily. Mice were culled at end of
hydrocortisone treatment to procure pancreata and terminal
blood. Pancreata were halved longitudinally for histology and
hormone measurements.
Biochemical analyses
Pancreatic tissues were homogenised and extracted using buffer
containing 20 mM Tris HCl (pH 7.5), 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA and 0.5% Triton X 100 and stored at 2
80uC. Protein concentrations were determined using Bradford
reagent (Sigma, Dorset, UK). Insulin in plasma and pancreatic
tissue extracts was determined by radioimmunoassay [33]. Total
GLP-1 and GIP in plasma and pancreatic extracts were
determined using specific enzyme linked immunoassays, following
manufacturer’s instructions (GLP-1 Total ELISA, EZGLP-1T-
36K, Millipore; rat/mouse GIP ELISA, EZRMGIP-55K, Milli-
pore). Glucagon in plasma and pancreatic tissue extracts was
determined using glucagon chemiluminescent assay (EZGLU-
30K, Millipore), following manufacturer’s instructions.
Tissue processing for histological analyses
Pancreatic tissues were fixed in 4% paraformaldehyde for 48 h
at 4uC and then processed using automated tissue processor (Leica
TP1020, Leica Microsystems, Nussloch, Germany). After embed-
ding in paraffin wax, tissues were sectioned at 7 mm thickness
using a microtome (Shandon finesse 325, Thermo scientific, UK)
and sections were picked at an interval of 10 sections. The tissue
sections were deparaffinised using Histoclear II (National Diag-
nostics, UK) and rehydrated through series of ethanol. After
antigen retrieval at 94uC for 20 min using citrate buffer (pH 6.0),
the sections were blocked using 10% normal goat serum and
incubated with primary antibodies (Table 1) overnight at 4uC. The
sections were then incubated with secondary antibody (Table 1)
for 45 min at 37uC. The slides were then mounted using anti-fade
mounting medium and viewed under FITC filter (488 nm) or
TRITC filter (594 nm) using a fluorescent microscope (an
Olympus system microscope, model BX51) and photographed
using the DP70 camera adapter system. Antibodies used were
highly specific and showed no cross-reactivity with related peptide
hormones.
Hematoxylin & eosin staining for demonstration of
lymphocytic infiltration
After rehydration using a series of ethanol solutions, the sections
were exposed to hematoxylin solution for 5 min and rinsed with
tap water, acid alcohol (0.25% HCl, 50% methanol) and again in
tap water prior to staining with eosin for 5 min. Following rinsing
with distilled water, sections were dehydrated using ethanol,
dipped in histo-clear II for 2 min and mounted using DePeX
mounting medium. The slides were then viewed using Olympus
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IX51 inverted microscope and photographed using a SPOT RT-
Ke camera (Diagnostic Instruments Inc, Sterling Heights, MI).
Image analysis
Cell‘F image analysis software (Olympus Soft Imaging Solu-
tions, GmbH) was used to analyse islet parameters including islet
area, alpha cell area and beta cell area, expressed as mm2. Number
of islets per mm2 of pancreas and islets with central alpha cells
were determined in a blinded fashion. For analysis of islet size
distribution, islets smaller than 10,000 mm2 were designated
‘small’, greater than 10,000 mm2 and lesser than 25,000 mm2 were
designated ‘medium’ and greater than 25,000 mm2 were designat-
ed ‘large’. Ki67 and TUNEL positive, insulin positive cells were
counted in a blinded manner and expressed as beta cell
proliferation or apoptosis frequency (% of total beta cells analysed).
Approximately 2000 beta cells were counted for Ki67 and
TUNEL analysis. Balance between proliferation and apoptosis
was expressed as ratio of proliferation to apoptosis frequencies.
Alpha cells containing GLP-1/GIP and negligible amounts of
glucagon (red or orange staining) were counted and expressed as
GLP-1 positive alpha cells/islet (% of total number of alpha cells).
For scoring insulitis [34], a grading system was used in which
grade 0 refers to no infiltration, grade 1 refers to peri-vascular or
peri-ductular infiltration, grade 2 refers to peri-islet infiltration and
intra-islet infiltration of less than 50% of islet and grade 3 refers to
intra-islet infiltration of more than 50% of islet. For blinded
observations, the investigator was unaware of the treatment groups
and codes were disclosed after statistical analyses.
Statistical analysis
Results are expressed as mean 6 S.E.M, n= 6 mice in each
group. Data were compared using One-way ANOVA, followed by
a Bonferroni Post hoc test using GraphPad PRISM software. Area
under the curve (AUC) analyses was calculated using the
trapezoidal rule with baseline subtraction. p,0.05 was considered
to be statistically significant.
Results
Streptozotocin and hydrocortisone significantly alter islet
parameters
Representative images showing insulin (red) and glucagon
(green) staining in islets of control, streptozotocin and hydrocor-
tisone treated C57BL/6, GLP-1RKO and GIPRKO mice are
shown in Figure 1A. In C57BL/6 mice, streptozotocin reduced
islet area, although not significantly, in association with an
increase in alpha-cell area and a marked reduction in beta-cell
area (p,0.001, Figure 1B, C, D). In incretin receptor KO mice,
streptozotocin significantly reduced islet area (p,0.05, p,0.01,
Figure 1B), with broadly similar increases in alpha-cell area (p,
0.05, p,0.001, Figure 1C), and decreases in beta-cell area as wild-
type mice (p,0.001, Figure 1D). In contrast to these effects of
streptozotocin, hydrocortisone significantly increased islet area,
alpha and beta cell areas in C57BL/6 mice (p,0.05, p,0.01, p,
0.001, Figure 1B, C, D). However, in incretin receptor KO mice,
hydrocortisone-induced increases in islet and beta cell areas were
significantly lower than wild-type controls (p,0.05, p,0.01,
Figure 1B, D). Hydrocortisone also markedly increased number
of islets per mm2 of pancreas in C57BL/6 mice but not in receptor
KO mice (p,0.001, Figure 2A). Indeed the number of islets in
hydrocortisone treated GIPRKO mice was less than C57BL/6
mice (p,0.01, Figure 2A). Hydrocortisone decreased numbers of
small islets and increased large islets in C57BL/6 mice with the
opposite being observed in both groups of KO mice (Figure 2B).
Streptozotocin significantly decreased number of islets in GLP-
1RKO mice but not in other groups (p,0.05, Figure 2A).
Streptozotocin had relatively little effect on size distribution with
tendency for decreased percentage of larger islets (Figure 2B).
Representative islets showing Ki67/insulin and TUNEL/
insulin staining in islets of control, streptozotocin and hydrocor-
tisone treated C57BL/6, GLP-1RKO and GIPRKO mice are
shown in Figure 3A. Streptozotocin and hydrocortisone markedly
increased beta cell apoptosis frequency in all groups (p,0.05, p,
0.001, Figure 3B). Hydrocortisone significantly increased beta cell
proliferation frequency in all groups (p,0.001, Figure 3B).
However, in KO mice, proliferation frequency was significantly
lesser than C57BL/6 mice (p,0.01, p,0.001, Figure 3C).
Table 1. Antibodies.
Primary antibodies
Target Host Clonality Dilution Source
Insulin Mouse Monoclonal 1:1000 Abcam, ab6995
Glucagon Guinea-pig Polyclonal 1:200 Raised in-house – PCA2/4
GLP-1 Rabbit Polyclonal 1:200 Raised in-house – XJIC8
GIP Rabbit Polyclonal 1:400 RIC34/111J, kindly donated by Professor L Morgan, Guildford, UK
Ki67 Rabbit Polyclonal 1:200 Abcam, ab15580
Secondary antibodies
Target Host Reactivity Dilution Source
IgG Goat Guinea-pig 1:400 Alexa Fluor 488, Invitrogen, UK
IgG Goat Mouse 1:400 Alexa Fluor 594, Invitrogen, UK
IgG Goat Rabbit 1:400 Alexa Fluor 488, Invitrogen, UK
IgG Goat Rabbit 1:400 Alexa Fluor 594, Invitrogen, UK
doi:10.1371/journal.pone.0101005.t001
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Figure 1. Islet analysis. A Representative islets showing insulin (red) and glucagon (green) immunoreactivity from C57BL/6, GLP-1RKO and GIPRKO
mice. B – Islet area (mm2). C - Alpha cell area (mm2). D – Beta cell area (mm2). Values are mean 6 SEM (n= 6). Dp,0.05, DDp,0.01, DDDp,0.001
compared to respective controls. *p,0.05, **p,0.01 compared to respective treatment of C57BL/6 mice.
doi:10.1371/journal.pone.0101005.g001
Figure 2. Islet analysis. A – Number of islets (count per mm2 of pancreas). B – Islet size distribution (% of total islets analysed). C – Blood glucose
(mmol/l). D – Plasma insulin (pmol/l). E – Glucose/Insulin molar ratio. Values are mean 6 SEM (n= 6). Dp,0.05, DDp,0.01, DDDp,0.001 compared to
respective controls. **p,0.01 compared to respective treatment of C57BL/6 mice.
doi:10.1371/journal.pone.0101005.g002
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Streptozotocin significantly decreased Ki67/TUNEL ration in all
groups, thus favoring beta cell apoptosis (p,0.05, p,0.01, p,
0.001, Figure 3D). Hydrocortisone significantly increased Ki67/
TUNEL ratio in C57BL/6 but did not alter Ki67/TUNEL ratio
in KO mice (p,0.001, Figure 3D). Ki67/TUNEL ratio was
markedly lower in hydrocortisone treated KO mice when
compared to C57BL/6 mice (p,0.01, p,0.001, Figure 3D).
Representative images of the co-localization of glucagon with
GLP-1 in islets of control, streptozotocin and hydrocortisone
treated C57BL/6, GLP-1RKO and GIPRKO mice are shown in
Figure 4A. GLP-1 immunoreactivity was detectable in alpha cells
of all untreated control groups. Streptozotocin significantly
increased GLP-1 positive cells per islet while decreasing coloca-
lization with glucagon (p,0.01, p,0.001, Figure 4B, C). In
untreated incretin receptor KO mice, GLP-1 positive alpha cells
were more numerous and colocalization with glucagon was less
than in C57BL/6 mice (p,0.05, Figure 4B, C). GLP-1 positive
alpha cells in hydrocortisone treated incretin receptor KO mice
were increased compared with C57BL/6 mice (p,0.05, p,0.01,
Figure 4B).
Representative images showing the co-localization of glucagon
with GIP in islets of all groups are shown in Figure 5A. GIP
positive alpha cells in hydrocortisone treated C57BL/6 mice were
more numerous than saline treated controls, while colocalization
with glucagon was less (p,0.001, Figure 5B, C). In GLP-1RKO
mice, streptozotocin and hydrocortisone did not alter GIP positive
alpha cells but significantly increased colocalization (p,0.05, p,
0.01, Figure 5C). There was a tendency towards increase in GIP
positive alpha cells in hydrocortisone treated GIPRKO mice while
colocalization with glucagon was decreased significantly (p,0.01,
Figure 5C). In untreated GLP-1RKO mice, GIP positive alpha
cells were more numerous and colocalization with glucagon was
less than in C57BL/6 mice (p,0.001, Figure 5B, C).
Streptozotocin induces lymphocyte infiltration in islets
Representative images showing hematoxylin and eosin staining
in islets of the various groups of mice are shown in Figure 6A.
Multiple low dose streptozotocin induced lymphocyte infiltration
in islets of all groups. The degree of infiltration was determined by
blinded analysis of insulitis grading [34]. Control and hydrocor-
tisone treated mice showed no signs of lymphocyte infiltration
(Figure 6B). In streptozotocin treated incretin receptor KO mice,
islets without insulitis (grade 0) were significantly less numerous
than C57BL/6 mice. Grade 2 and grade 3 insulitis were
significantly higher in GLP-1RKO and in GIPRKO mice,
respectively compared with streptozotocin treated C57BL/6 mice
(p,0.05, Figure 6C).
Streptozotocin and hydrocortisone alter pancreatic and
plasma hormone contents
Streptozotocin significantly increased blood glucose levels in all
groups of mice (p,0.001, Figure 2C) while insulin was consistently
undetectable in the circulation following streptozotocin treatment
(Figure 2D). Hydrocortisone did not significantly affect blood
glucose levels in any of the groups (Figure 2C). However it
significantly increased circulating levels of insulin in C57BL/6
mice but not in incretin receptor knockout mice (p,0.01,
Figure 2D). Plasma insulin was significantly increased compared
with hydrocortisone treated GIPRKO mice (p,0.01, Figure 2D).
Consistent with induction of insulin resistance, hydrocortisone
treatment significantly lowered glucose to insulin molar ratio
compared to untreated controls in all groups (p,0.05, p,0.01,
Figure 2E).
Streptozotocin increased pancreatic glucagon content in
C57BL/6, with no effect in other groups (p,0.05, Figure 7A).
Pancreatic glucagon content in streptozotocin treated GLP-1RKO
mice was significantly less than C57BL/6 mice (p,0.05,
Figure 7A). Hydrocortisone did not affect pancreatic glucagon
Figure 3. Proliferation and apoptosis. A Representative islets showing insulin (red) and Ki67 (green, indicated by arrows), insulin (red) and TUNEL
(green, indicated by arrows) immunoreactivity from C57BL/6, GLP-1RKO and GIPRKO mice. B – Beta cell apoptosis frequency (% of beta cells
analysed). C – Beta cell proliferation frequency (% of beta cells analysed). D – Ki67/TUNEL ratio. Values are mean 6 SEM of 6 observations unless
otherwise indicated. Dp,0.05, DDp,0.01, DDDp,0.001 compared to respective controls. *p,0.05, **p,0.01, ***p,0.001 compared to respective
treatment of C57BL/6 mice.
doi:10.1371/journal.pone.0101005.g003
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Figure 4. Glucagon and GLP-1 colocalization. A Representative islets showing glucagon (green) and GLP-1 (red) immunoreactivity from C57BL/
6, GLP-1RKO and GIPRKO mice. Dotted arrows indicate alpha cells expressing mainly of GLP-1 while block arrows indicate colocalization with
glucagon (yellow). B – Islets with GLP-1 positive alpha cells (% of total number of alpha cells analysed). C – GLP-1/Glucagon colocalization (Pearson’s
colocalization coefficient). Values are mean 6 SEM of 6 observations unless otherwise indicated. DDp,0.01, DDDp,0.001 compared to respective
controls. *p,0.05, **p,0.01 compared to respective treatment of C57BL/6 mice.
doi:10.1371/journal.pone.0101005.g004
Figure 5. Glucagon and GIP colocalization. A Representative islets showing glucagon (green) and GIP (red) immunoreactivity from C57BL/6,
GLP-1RKO and GIPRKO mice. Dotted arrows indicate alpha cells expressing mainly of GIP while block arrows indicate colocalization with glucagon
(yellow). B – GIP positive alpha cells (% of total number of alpha cells analysed). C – GIP/glucagon colocalization (Pearson’s coefficient of
colocalization). Values are mean 6 SEM of 6 observations. Dp,0.05, DDp,0.01, DDDp,0.001 compared to respective non-pregnant controls. ***p,
0.001 compared to respective treatment of C57BL/6 mice.
doi:10.1371/journal.pone.0101005.g005
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content in any of the groups. Streptozotocin increased pancreatic
GLP-1 and GIP content although not significantly in C57BL/6
mice (Figure 7B, C). The increase of pancreatic GLP-1 was
significant in streptozotocin treated GLP-1RKO mice (p,0.05,
Figure 7B). Hydrocortisone did not affect pancreatic GLP-1 or
GIP content in any of the groups (Figure 7 B, C). In untreated
incretin receptor knockout mice, pancreatic GIP content was
significantly higher than untreated C57BL/6 mice (p,0.05,
Figure 7C).
Streptozotocin significantly lowered pancreatic insulin content
in all groups of mice (p,0.05, p,0.001, Figure 7D) while
hydrocortisone increased pancreatic insulin content only in
C57BL/6 mice (p,0.05, Figure 7D). After hydrocortisone
treatment, pancreatic insulin content of C57BL/6 mice was
significantly more than GLP-1RKO mice (p,0.05, Figure 7D).
Streptozotocin significantly increased circulating levels of glucagon
in C57BL/6 and GIPRKO mice (p,0.05, Figure 7E). Whereas
hydrocortisone did not affect circulating glucagon in C57BL/6
and GLP-1RKO mice (Figure 7E), it significantly increased
plasma glucagon in GIPRKO mice (p,0.05, Figure 7F). Strep-
tozotocin increased plasma GLP-1 in C57BL/6 mice while it
decreased plasma GIP in both groups of incretin receptor
knockout mice (p,0.05, Figure 7H).
Discussion
Regulation of beta-cell function is under the control of
circulating nutrients, hormones, paracrine interactions and auto-
nomic nerves innervating the pancreatic islets [35]. Although
classically considered as enteroinsular hormones [36], this study
has examined the possibility that intra-islet production of GLP-1
or GIP, together with circulating incretins from the gut,
contributes to mechanisms controlling beta-cell function, partic-
ularly the regulation of beta-cell mass and adaptive responses to
beta cell toxins and insulin resistance. As with other recent studies,
we readily demonstrated GLP-1 and GIP in glucagon-containing
islet alpha-cells by immunohistochemistry using antisera specific
for glucagon or the two incretin hormones [14–16,18,19,21,24–
28]. Comparison of molar quantities measured by ELISA revealed
approximately similar amounts of GLP-1 and GIP in the pancreas,
corresponding to levels approximately 25% of pancreatic gluca-
gon. When released from within islets [20,21], local concentrations
of GIP and particularly GLP-1 are likely to be much greater than
the low circulating levels of the hormones and without significant
exposure to degradation by DPPIV [37].
Administration of multiple low doses of streptozotocin resulted
in severe insulitis, marked destruction of beta-cells, depletion of
pancreatic and plasma insulin, elevation of glucagon and severe
diabetes. This is consistent with the observed actions of the toxin to
induce lymphocytic infiltration and insulitis rather than simply
inducing chemical destruction of beta cells as occurs when
administered as a large single dose [38]. The marked loss of beta
cells resulted in remaining islets being marginally smaller,
irregularly shaped and exhibiting substantially increased alpha-
cell mass and pancreatic glucagon content. Interestingly, a
subpopulation of alpha cells predominantly expressed GLP-1,
supporting the idea that an increase in local production of GLP-1
may be involved in compensation for beta cell loss. There was also
a substantial increase in TUNEL staining beta cells and, in
contrast to other reports [39], little evidence of Ki-67 positive beta-
cell regeneration, giving rise to markedly decreased Ki-67 to
TUNEL ratio.
The possible involvement of GLP-1 and GIP in this compen-
satory islet response was evaluated further using GLP-1R KO and
Figure 6. Lymphocyte infiltration. A Representative islets showing hematoxylin and eosin staining of islets from C57BL/6, GLP-1RKO and GIPRKO
mice. B –Insulitis severity score (% of total number of islets analysed and graded according to level of lymphocyte infiltration). Values are mean 6
SEM of 6 observations. *p,0.05 compared to respective treatment of C57BL/6 mice.
doi:10.1371/journal.pone.0101005.g006
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GIPR KO mice maintained on the C57BL/6 background.
Compared with wild-type C57BL/6 controls, incretin receptor
KO mice displayed characteristic changes of islet morphology and
beta-cell mass as described previously [40]. GLP-1 and GIP were
expressed in islet alpha cells of all groups of mice. Treatment of
incretin receptor KO mice with multiple low dose streptozotocin
resulted in a slightly greater severity of islet damage than normal
mice treated with the toxin. This was reflected by decreased islet
numbers in GLP-1R KO mice and decreases in islet size and beta
cell area together with increased alpha cell mass in both transgenic
mouse models. Knock-out of GLP-1R also resulted in increased
pancreatic GLP-1 without change of pancreatic glucagon or
circulating hormone levels, suggesting that insulin deficiency and/
or receptor deletion affects cellular GLP-1 production from the
proglucagon precursor. In contrast, circulating GIP was decreased
in in both groups of receptor knock-out mice without affecting
tissue stores. Irrespective of these changes, deletion of receptors for
either incretin hormone did not greatly affect the course of severe
insulin deficient diabetes. This likely reflects the severe hypergly-
caemia and substantial level of damage inflicted on beta cells, as
witnessed by lack of beta cell regeneration and markedly decreased
Ki67/TUNEL ratios in control diabetic C57BL/6 mice.
The metabolic and islet cell responses to hydrocortisone
treatment were quite different to those induced by multiple low
doses of streptozotocin. Thus, C57BL/6 animals exhibited
markedly increased islet, beta and alpha cell areas associated with
increased numbers of medium and large sized islets. Ki67
proliferation was enhanced and there was only a small level of
apoptosis as judged by TUNEL staining. Both pancreatic and
plasma levels of insulin but not glucagon were markedly elevated
but glucose concentrations were relatively normal, indicating the
effectiveness of markedly enhanced beta cell activity to overcome
severe insulin resistance [41]. In addition to such metabolic actions
on islets, we cannot discount that hydrocortisone might also exert
direct effects on the function of beta and alpha cells [42]. Intra-islet
expression of GLP-1 and GIP was clearly evident with increased
numbers of alpha cells mainly producing GIP. Pancreatic and
circulating levels of GLP-1 and GIP were unchanged, thereby
excluding a significant role of intestinally-derived hormones in
cellular and metabolic effects. Thus, ablation of intra-islet, as
opposed to circulating GLP-1 or GIP, actions using receptor KO
mice appear to be responsible for loss of the normal compensatory
increases of islet numbers and morphology induced by hydrocor-
tisone, with islet size and beta cell mass remarkably less than
observed in normal C57BL/6 mice. Numbers of islets in GIPR
KO mice were also less than hydrocortisone treated C57BL/6
mice. Accordingly, it appears that the sole or dual additive actions
of GLP-1 and GIP produced locally by alpha cells may be
particularly important in terms of islet responses to increased
functional demand.
These combined observations suggest that GLP-1 and GIP
produced largely by islet alpha cells may play a hitherto unproven
role in islet adaptation to insulin resistance and the control of
glucose homeostasis. Further studies using mice with specific
knock-out of incretin receptors in islets would be useful to
investigate this further. Decreased beta cell mass and inability to
Figure 7. Pancreatic and plasma levels of hormones. A – Pancreatic glucagon content (pmol/mg protein). B – Pancreatic GLP-1 content (pmol/
mg protein). C – Pancreatic GIP content (pmol/mg protein). D – Pancreatic insulin content (nmol/mg protein). E – Plasma glucagon (pmol/l). F –
Plasma total GLP-1 (pmol/l). G – Plasma GIP (pmol/l). Values are mean 6 SEM of 4–6 observations unless otherwise indicated. Dp,0.05, DDDp,0.001
compared to respective controls. *p,0.05 compared to respective treatment of C57BL/6 mice.
doi:10.1371/journal.pone.0101005.g007
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secrete appropriate amounts of insulin are classical features of
gestational as well as type 1 and type 2 diabetes [43,44]. Since
existing therapies target insulin replacement or enhancing insulin
secretion/action [45], intra-islet production of GLP-1 and GIP
through manipulation of proconvertase enzymes may represent a
therapeutically useful way to increase beta cell mass and
physiological insulin secretion.
Author Contributions
Conceived and designed the experiments: PRF. Performed the experi-
ments: SV RCM. Analyzed the data: SV RCM. Contributed reagents/
materials/analysis tools: SV RCM PRF. Contributed to the writing of the
manuscript: SV RCM PRF. Contributed to interpretation of data and
revised the manuscript for intellectual content: BT.
References
1. Drucker DJ (2007) The role of gut hormones in glucose homeostasis. J Clin
Invest 117: 24–32.
2. Green BD, Flatt PR (2007) Incretin hormone mimetics and analogues in
diabetes therapeutics. Best Pract Res Clin Endocrinol Metab 21: 497–516.
3. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409–
1439.
4. McIntosh CH, Widenmaier S, Kim SJ (2009) Glucose-dependent insulinotropic
polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 80: 409–471.
5. Irwin N, Gault V, Flatt PR (2010) Therapeutic potential of the original incretin
hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity,
osteoporosis and Alzheimer’s disease? Expert Opin Investig Drugs 19: 1039–
1048.
6. Irwin N, Flatt PR (2009) Therapeutic potential for GIP receptor agonists and
antagonists. Best Pract Res Clin Endocrinol Metab 23: 499–512.
7. Barnett AH, O’Hare P (2013) Cardiovascular benefits of incretins. BMJ 347:
f4382.
8. Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of
incretin hormone action. Cell Metab 17: 819–837.
9. Irwin N, Flatt PR (2013) Enteroendocrine hormone mimetics for the treatment
of obesity and diabetes. Curr Opin Pharmacol 13: 989–995.
10. Nauck MA, Baranov O, Ritzel RA, Meier JJ (2013) Do current incretin mimetics
exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
Diabetologia 56: 1878–1883.
11. Flatt PR, Bailey CJ, Green BD (2009) Recent advances in antidiabetic drug
therapies targeting the enteroinsular axis. Curr Drug Metab 10: 125–137.
12. Heller RS, Aponte GW (1995) Intra-islet regulation of hormone secretion by
glucagon-like peptide-1-(7–36) amide. Am J Physiol 269: G852–60.
13. Masur K, Tibaduiza EC, Chen C, Ligon B, Beinborn M (2005) Basal receptor
activation by locally produced glucagon-like peptide-1 contributes to maintain-
ing beta-cell function. Mol Endocrinol 19: 1373–1382.
14. Hansen AM, Bodvarsdottir TB, Nordestgaard DN, Heller RS, Gotfredsen CF,
et al. (2011) Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in
Psammomys obesus–an adaptive response to hyperglycaemia? Diabetologia 54:
1379–1387.
15. Whalley NM, Pritchard LE, Smith DM, White A (2011) Processing of
proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism
enabling GLP-1 to act on beta-cells? J Endocrinol 211: 99–106.
16. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, et al. (2012) A
local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.
Diabetologia 55: 3262–3272.
17. Thyssen S, Arany E, Hill DJ (2006) Ontogeny of regeneration of beta-cells in the
neonatal rat after treatment with streptozotocin. Endocrinology 147: 2346–
2356.
18. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, et al. (2011)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-
1 secretion from L cells and alpha cells. Nat Med 17: 1481–1489.
19. Irwin N, Montgomery IA, Moffett RC, Flatt PR (2013) Chemical cholecysto-
kinin receptor activation protects against obesity-diabetes in high fat fed mice
and has sustainable beneficial effects in genetic ob/ob mice. Biochem Pharmacol
85: 81–91.
20. Salehi M, Aulinger B, Prigeon RL, D’Alessio DA (2010) Effect of endogenous
GLP-1 on insulin secretion in type 2 diabetes. Diabetes 59: 1330–1337.
21. Fujita Y, Wideman RD, Asadi A, Yang GK, Baker R, et al. (2010) Glucose-
dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells
and promotes insulin secretion. Gastroenterology 138: 1966–1975.
22. Ugleholdt R, Poulsen ML, Holst PJ, Irminger JC, Orskov C, et al. (2006)
Prohormone convertase 1/3 is essential for processing of the glucose-dependent
insulinotropic polypeptide precursor. J Biol Chem 281: 11050–11057.
23. Gault VA, Porter DW, Irwin N, Flatt PR (2011) Comparison of sub-chronic
metabolic effects of stable forms of naturally occurring GIP (1-30) and GIP (1-42)
in high-fat fed mice. J Endocrinol 208: 265–271.
24. Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated
forms of glucagon-like peptide I are synthesized in the rat intestine and the
pancreas. J Biol Chem 265: 8001–8008.
25. Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, et al. (1992)
Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig
and man. Eur J Clin Invest 22: 283–291.
26. Nie Y, Nakashima M, Brubaker PL, Li QL, Perfetti R, et al. (2000) Regulation
of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in
diabetic rats. J Clin Invest 105: 955–965.
27. Wideman RD, Covey SD, Webb GC, Drucker DJ, Kieffer TJ (2007) A switch
from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-
cells is accompanied by differential processing of proglucagon and improved
glucose homeostasis in mice. Diabetes 56: 2744–2752.
28. Kilimnik G, Kim A, Steiner DF, Friedman TC, Hara M (2010) Intraislet
production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic
alpha-cells in mouse models of ss-cell regeneration. Islets 2: 149–155.
29. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP.
Gastroenterology 132: 2131–2157.
30. Irwin N, McClean PL, Hunter K, Flatt PR (2009) Metabolic effects of sustained
activation of the GLP-1 receptor alone and in combination with background
GIP receptor antagonism in high fat-fed mice. Diabetes Obes Metab 11: 603–
610.
31. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, et al. (1996)
Glucose intolerance but normal satiety in mice with a null mutation in the
glucagon-like peptide 1 receptor gene. Nat Med 2: 1254–1258.
32. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, et al. (2004) Gluco-
incretins control insulin secretion at multiple levels as revealed in mice lacking
GLP-1 and GIP receptors. J Clin Invest 113: 635–645.
33. Flatt PR, Bailey CJ (1981) Abnormal plasma glucose and insulin responses in
heterozygous lean (ob/+) mice. Diabetologia 20: 573–577.
34. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, et al. (2005) Oral
probiotic administration induces interleukin-10 production and prevents
spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabeto-
logia 48: 1565–1575.
35. Kelly C, McClenaghan NH, Flatt PR (2011) Role of islet structure and cellular
interactions in the control of insulin secretion. Islets 3: 41–47.
36. Creutzfeldt W (2001) The entero-insular axis in type 2 diabetes–incretins as
therapeutic agents. Exp Clin Endocrinol Diabetes 109 Suppl 2: S288–303.
37. Flatt PR, Bailey CJ, Green BD (2008) Dipeptidyl peptidase IV (DPP IV) and
related molecules in type 2 diabetes. Front Biosci 13: 3648–3660.
38. O’Brien BA, Harmon BV, Cameron DP, Allan DJ (1996) Beta-cell apoptosis is
responsible for the development of IDDM in the multiple low-dose
streptozotocin model. J Pathol 178: 176–181.
39. Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, et al. (2012)
Reduction of both beta cell death and alpha cell proliferation by dipeptidyl
peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.
Diabetologia 55: 404–412.
40. Hansotia T, Drucker DJ (2005) GIP and GLP-1 as incretin hormones: lessons
from single and double incretin receptor knockout mice. Regul Pept 128: 125–
134.
41. Bailey CJ, Flatt PR (1982) Hormonal control of glucose homeostasis during
development and ageing in mice. Metabolism 31: 238–246.
42. Swali A, Walker EA, Lavery GG, Tomlinson JW, Stewart PM (2008) 11beta-
Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion
in pancreatic islets. Diabetologia 51: 2003–2011.
43. Nadal A, Alonso-Magdalena P, Soriano S, Ropero AB, Quesada I (2009) The
role of oestrogens in the adaptation of islets to insulin resistance. J Physiol 587:
5031–5037.
44. Thorens B (2013) The required beta cell research for improving treatment of
type 2 diabetes. J Intern Med 274: 203–214.
45. Kaiser D, Oetjen E (2014) Something old, something new, and something very
old - drugs for treating type 2 diabetes. Br J Pharmacol.
Role of Incretin Hormones in Beta Cell Adaptation in Cellular Stress
PLOS ONE | www.plosone.org 9 June 2014 | Volume 9 | Issue 6 | e101005
